Printer Friendly

LIDAK PHARMACEUTICALS ANNOUNCES RESIGNATIONS

 LIDAK PHARMACEUTICALS ANNOUNCES RESIGNATIONS
 LA JOLLA, Calif., Dec. 17 /PRNewswire/ -- LIDAK Pharmaceuticals


(NASDAQ: LDAKU, LDAKA) announced today the Drs. Eric P. Neibart and Donald E. Mosier have resigned from the board of directors of the company. Neibart's resignation will be effective Dec. 18, 1991; Mosier's resignation was effective Dec. 16, 1991.
 Mosier also resigned from his positions as vice president and chief scientific officer of the company. Mosier has expressed his intent to remain as an employee of the company until certain contractual obligations to outside parties are fulfilled. Pending Mosier's replacement, Dr. David H. Katz, chairman and chief executive officer of the company, will share Mosier's duties with certain other members of the senior scientific staff.
 Mosier cited as reasons for his resignation his disagreements with, and lack of confidence in, a majority of the board and management over its approach to management changes and restructuring of the company and its ability "to lead the company out of its current problems." He also stated that as chief scientific officer he had been placed in the "untenable position ... of supporting scientific claims with which I disagree or which I believe to be overstated."
 "We regret Dr. Mosier's resignation," said Katz. "Our company is in the development stage and our plans, including the proposed restructuring, are the subject of ongoing review and consideration.
 "Moreover," stated Katz, "all of our technologies are the subject of continuing research, testing and outside evaluation; at this very moment recognized experts are completing independent evaluations of our principal technologies.
 "Dr. Mosier has never been required or expected to support claims with which he disagreed. No claims have been overstated but, on the contrary, are made subject to the caveat that our technologies require further testing and evaluation," concluded Katz.
 The company has filed with the Securities and Exchange Commission a current report on Form 8-K further discussing this event. A copy of the report will be made available upon request.
 -0- 12/17/91
 /CONTACT: David H. Katz, M.D., chairman and CEO, 619-450-1538 or Michael H. Lorber, VP and CFO, 619-558-0364, both of LIDAK Pharmaceuticals; or Elizabeth A. Gard of Rifkind Pondel & Parsons, 310-207-9300, for LIDAK/
 (LDAKU LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER


EH-SE -- LA026 -- 3200 12/17/91 18:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1991
Words:381
Previous Article:DIGITAL BIOMETRICS ANNOUNCES MARKETING AND SERVICE AGREEMENT WITH PRINTRAK INTERNATIONAL
Next Article:THE FLIGHT INTERNATIONAL GROUP, INC., ANNOUNCES SECOND QUARTER RESULTS
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS ISSUES STATEMENT ON RESIGNATION OF DONALD E. MOSLER
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS COMPLETES STAFFING OF ITS CLINICAL DEVELOPMENT ADVISORY PANEL WITH ADDITION OF GALLO
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters